Guardion health sciences, inc. (GHSI)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Operating Activities
Net loss

-2,346,913

-4,055,755

-2,385,376

-3,052,078

-1,385,099

-1,476,190

-2,148,192

-1,809,564

-2,333,461

-2,196,107

-1,584,383

-855,668

-669,011

-2,307,522

-1,141,044

-1,350,628

-949,203

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

23,114

267,533

72,685

69,026

68,102

72,658

74,454

75,538

73,022

70,952

16,538

15,786

15,545

15,542

25,772

10,323

8,492

Amortization of debt discount

-

0

0

233,455

16,545

-

-

-

-

-

-

-

-

39,955

97,905

184,366

109,455

Amortization of lease right

37,983

55,218

31,651

31,069

30,502

-

-

-

-

-

-

-

-

-

-

-

-

Accrued interest expense included in notes payable

-

0

0

-239

1,027

-

0

0

0

-

1,046

630

13,116

25,160

20,724

23,679

17,148

Stock-based compensation

67,606

78,488

56,688

186,765

56,231

189,815

350,337

277,372

777,513

944,336

582,014

302,295

103,623

147,100

262,528

369,929

8,127

Stock-based compensation - officer and director

436,287

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation – related parties

-

-

-

-

-

0

0

0

0

-13,000

88,000

50,893

57,158

299,561

149,187

293,206

240,892

Change in fair value of derivative warrants

8,944

-33,795

-31,322

-413,866

186,034

-

-

-

-

-

-

-

-

168,006

161,089

146,796

99,782

Changes in operating assets and liabilities:
(Increase) decrease in -
Accounts receivable

-47,255

56,410

-13,993

20,834

-13,116

11,193

-12,833

-27,583

-15,345

19,162

1,842

-251

240

1,297

-431

-314

-15

Inventories

131,195

-9,414

1,669

14,867

-54,178

-23,270

-31,090

229,439

28,188

-23,302

-23,564

58,280

6,025

-21,877

32,018

-7,170

10,465

Prepaid expenses

-568,199

-

-

-

-3,388

-

-

-

-

-

-

-

-

-

-

-

-

Deposits and prepaid expenses

-

-

-

-

-

9,036

12,906

-87,567

-2,486

89,420

20,619

-31,157

8,369

197

2,574

-5,997

-11,361

Increase (decrease) in -
Accounts payable

179,093

-

-

-

463,900

-

-

-

-

-

-

-

-

-

-

-

-

Customer deposit

437,500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

-

-

-

-

-

145,806

-189,319

10,878

135,324

-173,545

-5,816

-19,641

77,083

-983

-5,060

-31,806

122,454

Lease liability

36,803

53,986

30,058

28,756

28,088

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses

109,918

-

-

-

-59,145

-

-

-

-

-

-

-

-

-

-

-

-

Accrued and deferred rent costs

-

-

-

-

-

58,979

10,815

-4,854

4,429

-12,697

10,074

-45,168

-28,456

-4,028

-26,920

-1,919

-21,920

Net cash used in operating activities

-1,735,410

-1,840,954

-1,695,354

-1,907,611

-586,085

-885,891

-863,882

-1,070,528

-1,353,530

-1,488,951

-891,424

-577,745

-445,576

-

-

-

-

Investing Activities
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-342,573

-363,862

Purchase of property and equipment

40,733

7,971

104,171

54,119

4,815

31,932

91,238

41,962

95,111

12,077

19,703

5,500

0

159

2,024

0

1,171

Purchase of intellectual property

-

-

-

-

-

0

0

0

50,000

0

0

0

0

-

-

-

-

Net cash used in investing activities

-40,733

-7,971

-104,171

-54,119

-4,815

-31,932

-91,238

-41,962

-145,111

-12,077

-14,808

-5,500

0

-

-

-

-

Financing Activities
Proceeds from issuance of preferred stock

-

-

-

-

-

0

0

0

0

0

2,005,000

400,000

700,000

100,000

500,000

545,000

0

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-1,171

Proceeds from issuance of convertible notes

-

0

0

0

250,000

-

-

-

-

-

-

-

-

0

0

0

136,000

Proceeds from issuance of promissory notes - related party

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

50,000

90,000

Proceeds from issuance of promissory notes

-

0

0

0

100,000

0

0

0

0

0

0

0

100,000

0

50,000

145,000

25,000

Payments on promissory note

-

-

-

-

-

0

0

0

0

25,000

110,000

0

14,000

14,000

7,000

130,000

0

Proceeds from exercise of warrants

3,550,781

17,000

22,500

100,625

31,250

15,000

0

0

1,460

0

0

0

0

-

-

-

-

Payments on line of credit

-

-

-

-

-

0

0

0

30,535

1,860

0

0

0

-

-

-

-

Deferred financing costs of IPO

-

-

-

-268,000

287,000

-

-

-

-

-

-

-

-

-

-

-

-

Decrease in due to related parties

-

-

-

-

-

-108,019

-9,455

-19,494

-9,165

-6,638

-16,549

35,931

41,906

43,798

61,500

25,000

85,300

Net cash provided by financing activities

3,550,781

7,409,467

4,985,840

4,156,077

94,250

486,981

-9,455

-19,494

-38,240

4,966,503

1,878,451

435,931

827,906

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

635,000

336,300

Cash:
Net increase (decrease)

1,774,638

5,560,542

3,186,315

2,194,347

-496,650

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease

-

-

-

-

-

-430,842

-964,575

-1,131,984

-1,536,881

3,465,475

972,219

-147,314

382,330

-327,520

112,496

292,427

-28,733

Supplemental disclosure of cash flow information:
Cash paid for - Interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

385

0

0

Income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

Non-cash financing activities:
Fair value of warrants issued in connection with convertible notes

-

0

0

0

436,034

-

-

-

-

-

-

-

-

-

-

-

-

Recording of lease asset and liability upon adoption of ASU 2016-02

-

57,936

0

-57,936

721,154

-

-

-

-

-

-

-

-

-

-

-

-

Reclass of prepaid costs to inventory

308,178

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reclass of equipment sold from property and equipment to equipment held for sale

8,771

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of warrants issued in connection with promissory and convertible notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

24,726

0

120,639

124,710

Beneficial conversion feature associated with promissory and convertible notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

31,175

39,774